Muted Pharmaceutical Market Growth In 2010

BMI View: Despite the threat of austerity measures, the government's focus on cost-containment within the pharmaceuticals and healthcare sector and the impact of generic competition as a result of the patent cliff, we expect the Netherlands to remain attractive to innovative drugmakers. Per-capita spending on pharmaceuticals and healthcare is high, there is a sizeable pensionable population and regulations are transparent - factors BMI believes will continue to bring in substantial income for companies operating in the country.

To read the full article, please choose one of the following options: